Maze Therapeutics (NASDAQ:MAZE) Announces Quarterly Earnings Results

Maze Therapeutics (NASDAQ:MAZE) posted its quarterly earnings data on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08, FiscalAI reports.

Here are the key takeaways from Maze Therapeutics’ conference call:

• Maze reported MZE829 achieved a 36% mean UACR reduction at 12 weeks in broad AMKD, exceeding the pre-specified 30% proof-of-concept threshold, with pronounced subgroup results of 61.8% in FSGS and 48.6% in non-diabetics.
• The company said MZE829 was well-tolerated with no serious adverse events and only mild-to-moderate treatment-related AEs, supporting further clinical development.
• Based on these data, Maze intends to advance MZE829 into a pivotal program and will engage regulators and share development plans and updates over the coming year.
• Findings come from a small, open-label cohort (15 patients, 12 per‑protocol) over 12 weeks with limited diabetic-subgroup data and no meaningful eGFR or long-term outcomes yet, leaving uncertainty about durability and generalizability.
• Maze highlighted a strong near-term financial and pipeline position — expected cash runway into 2028, a $20 million milestone from Shionogi after first‑patient dosing, and multiple programs (including MZE782) progressing toward Phase II.

Maze Therapeutics Trading Down 0.1%

Shares of MAZE opened at $31.71 on Friday. The firm has a market capitalization of $1.53 billion, a P/E ratio of -9.82 and a beta of 4.47. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $53.65. The firm has a fifty day moving average price of $45.81 and a 200-day moving average price of $37.51.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $110 and lifted EPS forecasts across 2026–2030, reiterating a “Buy” rating — a strong fundamental endorsement that supports upside expectations. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
• Positive Sentiment: BTIG reaffirmed a “Buy” rating (with a $46 target), providing additional analyst support following the trial news. Maze Therapeutics Earns “Buy” Rating from BTIG Research
• Positive Sentiment: Maze reported positive Phase 2 HORIZON topline data for MZE829, which the company and some analysts called the first clinical proof-of-concept in APOL1-mediated kidney disease — a major clinical milestone that underpins longer-term value. Phase 2 HORIZON topline data article
• Neutral Sentiment: An insider reported the sale of ~15,000 shares (executed via option exercise), disclosed publicly — a liquidity event that can be interpreted various ways but was not described as indicative of corporate problems. Insider sale disclosure
• Negative Sentiment: Despite the positive topline readout, investors sold heavily, and coverage noted the stock plunged roughly one-third at points on “mixed” midstage data interpretation — signaling investor concern about durability, subgroup results, or commercial assumptions. That volatility weighs on near-term price performance. Market reaction / mixed data article
• Negative Sentiment: Investor law firm Johnson Fistel announced an investigation into potential claims involving Maze executives, which can increase regulatory/legal risk and add selling pressure while inquiries are ongoing. Johnson Fistel investigation notice

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Wedbush upped their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a report on Monday, March 16th. Truist Financial started coverage on shares of Maze Therapeutics in a research report on Tuesday, March 17th. They issued a “buy” rating and a $68.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright upped their target price on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $64.11.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $49.10, for a total transaction of $736,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Amy Bachrodt sold 5,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at $596,908.60. This represents a 27.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 245,000 shares of company stock valued at $10,504,792 in the last three months.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of MAZE. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the last quarter. California State Teachers Retirement System grew its stake in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after buying an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock valued at $247,000 after buying an additional 931 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in Maze Therapeutics in the fourth quarter valued at about $39,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.